17 May 2016
HEBEI CHANGSHAN BIOCHEM PHARMA AND ALBUMEDIX ENTER INTO AGREEMENT FOR DEVELOPMENT OF PATIENT-FRIENDL…Read more
12 May 2016
European Commission Approves IDELVION®, A long acting Hemophilia treatment using Albumedix Albumin-b…Read more
15 Mar 2016
Albumedix Drug Delivery Technology Used by CSL Behring to Achieve 14 Day Dosing for Haemophilia B Th…Read more
09 Feb 2016
Albumedix Announces Exclusive Commercialization Agreement with ThioLogics for its Proprietary Drug C…Read more
28 Jan 2016
Albumedix and Eleven Biotherapeutics Announce Albumin Variant Technology AgreementRead more
18 Jan 2016
Novozymes separates its biopharma-activities to form independent companyRead more
Albumedix has developed a range of high-quality, animal origin-free recombinant human albumin products, Recombumin®, from our proprietary Saccharomyces yeast strains. Recombumin® is the world's first and only supply of commercial recombinant human albumin, approved for use in the manufacture of human therapeutics.
Proven as an effective versatile stabilizer with the ability to protect challenging drug, cell and vaccine products from aggregation, non-specific adsorption, and oxidation, Recombumin® enables drug developers to readily formulate otherwise instable drug candidates and to simplify their formulation strategy. As a result, the unique technology offers a fast, established pathway to clinic and ultimately to market.
Delivered by Albumedix and its partners, the Veltis® platform optimizes drug dosing through its ability to control dose size and frequency as well as drug loading. These effects are achieved using recombinant human albumin and albumin variants implemented by genetic fusion or chemical conjugation to drug candidates.
Veltis® offers drug developers a superior and highly versatile drug delivery platform that presents new opportunities to optimize the pharmacokinetics and efficacy of their peptides, proteins or small molecule drugs to achieve stricter patient compliance for improved therapeutic impact.